Kris (Kestutis) has extensive experience in transfer pricing and specializes in operational transfer pricing, DEMPE analysis and intangibles. Previously, he was a Transfer Pricing Director at EY Belgium. He has an advanced diploma in international taxation from the Chartered Institute of Taxation in the UK. Kris is a lawyer and holds LL.M. degree. In addition, he completed financial analysis and blockchain strategy programmes at London Business School and Oxford University.
November 2019
When you’re negotiating royalty rates for a licensing deal or carrying out a transfer pricing analysis on an intercompany transaction, it can be useful to see what royalties other companies charged in comparable circumstances.
November 2019
When you use the RoyaltyRange database, you get access to some of our data at no cost. This is because we want you to feel sure that you’ve found the right data before you pay for it.
November 2019
Imagine having real, up-to-date medical device royalty rates instantly. In just a few minutes, you could be looking at the latest royalty rates for medical devices and applying them to the licensing agreement or transfer pricing analysis you’re conducting.
October 2019
In the construction industry, it is common for assets and intellectual property rights to be licensed.
Assets that are often licensed include trademarked designs, patented technologies, innovative systems and new products. In exchange for their use, a licensee must pay royalties to the designer or inventor.
August 2019
A patent royalty agreement is a contract that outlines the terms under which a licensee can use a licensor’s patented product.
A ‘reasonable royalty rate’ is an estimation of damages in patent infringement cases. It is often referred to as established royalty that a licensee would pay for the rights to the patented invention in a hypothetical negotiation.
Third-party franchise agreements can provide highly useful information for transfer pricing professionals analyzing franchise transactions involving intangibles.
There are no typical technology licensing fees or patent licensing fees. Technology licensing agreements are complex and, as such, technology and patent licensing fees differ greatly.
License agreements and royalties for inventions are complicated, and broad royalty rates averages often overlook the nuances and complexities of individual licensing situations.
In this article, we explain how to determine royalty rates for pharma licensing deals using the market approach (using comparable pharmaceutical royalty rates to set your own).